Sector News

Australia’s CSL buys Novartis flu vaccine unit for $275 mln

October 27, 2014
Life sciences
(Reuters) – Australia’s CSL Ltd , the world’s largest blood products company, said on Monday it had agreed to buy Novartis AG’s global influenza vaccine business for $275 million, part of the Swiss drugmaker’s drive to focus on its best assets.
 
The sale of the flu business will conclude Novartis’ overhaul of its units which it had flagged in April, aimed at strengthening its cancer business and exiting underperforming operations.
 
Novartis said in April GlaxoSmithKline was buying its vaccines business, excluding flu, for $5.25 billion plus potential milestone payments of up to $1.8 billion and royalties.
 
The sale of its flu business to CSL will trigger an exceptional pretax impairment charge of approximately $1.1 billion, as the selling price is below the book value of the assets, Novartis said in a statement on Monday.
 
The charge will be excluded from the Swiss drugmaker’s core results and a one-time operating income gain expected from the deal with GSK will compensate for the charge, it said.
 
Combining the Novartis unit with CSL subsidiary bioCSL would create the No.2 player in the $4 billion global influenza vaccine industry, CSL said in a statement to the Australian stock exchange.
 
CSL, which said it would fund the deal with surplus cash, estimated integration costs at $100 million, while synergy benefits were seen at $75 million a year by 2020.
 
The deal is expected to close in the second half of 2015, pending regulatory approval, Novartis said. (Reporting by Lincoln Feast in Sydney and Alice Baghdjian in Zurich; Editing by Robin Pomeroy and David Holmes)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]